Innovation Pharmaceuticals Inc (IPIX)

[macnqueso]

In this case the P2b trial is clinically indicated because of findings in the P2a trial... namely that Brilacidin is highly effective in very short dosing protocols... and not really anymore effective in longer dosing protocols... and the possibility that shorter dosing cycle will further reduce any adverse side effects, which are already quite manageable, but less of this is even better... so before launching into a very expensive P3 trial designed to achieve stat sig level of efficacy... it makes sense to do a P2b with shorter dosing cycle as confirmation of P2a findings... data from P2b will inform the trial design for P3...